Find AI Tools
PathAI screenshot

What is PathAI?

PathAI is a medical technology company that builds artificial intelligence software for pathology. Its AISight platform is a cloud-native workflow system for case management, whole-slide image management and AI analysis used by laboratories, health systems and research centres, with the AISight Dx version cleared by the FDA for primary diagnosis. The company also offers a menu of AI algorithms for quality control, tumour detection and biomarker quantification, plus services that support pharmaceutical drug development and clinical trials.

Key Features

AISight platform

Cloud-native workflow system that acts as a central hub for case management, image management and AI tools in histopathology labs.

AISight Dx

FDA 510(k) cleared and CE-IVDR marked platform that can be used for primary diagnosis in clinical settings.

AI algorithm portfolio

Over 20 products including TumorDetect, ArtifactDetect and AIM biomarker tools measuring PD-L1, HER2, ER, PR and Ki-67.

AISight Link API

Open environment that lets labs integrate PathAI algorithms and third-party algorithms from partners such as Paige, Visiopharm, DeepBio and DoMore Dx.

Scanner interoperability

Works with major scanner brands including Hamamatsu, Leica, Roche and Philips and integrates with laboratory information systems.

BioPharma services

Supports drug development through biomarker discovery, real-world data and clinical trial analysis for pharmaceutical partners.

Pathologist network and data

Access to a network of board-certified pathologists and millions of annotations used to train and validate algorithms.

Pros & Cons

Advantages

  • AISight Dx holds FDA clearance and a CE-IVDR mark for primary diagnosis, which gives it regulatory standing that many digital pathology tools lack.
  • The cloud-native architecture is browser accessible and avoids the need for additional on-site hardware, supporting faster deployment.
  • An open API lets laboratories combine PathAI algorithms with third-party algorithms from established partners rather than being locked to one vendor.
  • Broad scanner and laboratory information system interoperability reduces friction when fitting into existing lab infrastructure.
  • The platform is backed by a large pathologist network and millions of annotations that underpin algorithm training and validation.

Limitations

  • Pricing is not published and is negotiated per enterprise contract, so smaller labs cannot assess affordability without contacting sales.
  • Many of the AI algorithms remain labelled For Research Use Only in the United States rather than cleared for clinical diagnosis.
  • The platform is aimed at laboratories, health systems and biopharma, so it is not relevant to individual clinicians or general users.
  • Adoption depends on compatible scanners and integration work, which can lengthen and complicate the onboarding process.

Use Cases

Pathology laboratories use AISight to digitise slides and manage case and image workflows in one cloud platform.

Clinical pathologists use the FDA-cleared AISight Dx to perform primary diagnosis on digitised slides.

Labs run AI algorithms such as TumorDetect and biomarker quantification to prioritise cases and assist scoring.

Pharmaceutical companies use PathAI BioPharma services for biomarker discovery and clinical trial analysis during drug development.

Health systems and reference laboratories integrate third-party algorithms through the AISight Link API to extend their AI menu.

Research centres apply research-use algorithms to characterise disease in tissue samples at scale.